Prostate Carcinoma Skeletal Metastases: Cross-talk Between Tumor and Bone
Overview
Affiliations
The majority of men with progressive prostate cancer develop metastases with the skeleton being the most prevalent metastatic site. Unlike many other tumors that metastasize to bone and form osteolytic lesions, prostate carcinomas form osteoblastic lesions. However, histological evaluation of these lesions reveals the presence of underlying osteoclastic activity. These lesions are painful, resulting in diminished quality of life of the patient. There is emerging evidence that prostate carcinomas establish and thrive in the skeleton due to cross-talk between the bone microenvironment and tumor cells. Bone provides chemotactic factors, adhesion factors, and growth factors that allow the prostate carcinoma cells to target and proliferate in the skeleton. The prostate carcinoma cells reciprocate through production of osteoblastic and osteolytic factors that modulate bone remodeling. The prostate carcinoma-induced osteolysis promotes release of the many growth factors within the bone extracellular matrix thus further enhancing the progression of the metastases. This review focuses on the interaction between the bone and the prostate carcinoma cells that allow for development and progression of prostate carcinoma skeletal metastases.
Role of Chemokines and Cytokines in Prostate Cancer Skeletal Metastasis.
Shiozawa Y, Parajuli K, Pienta K, Taichman R Curr Osteoporos Rep. 2024; 23(1):3.
PMID: 39585513 DOI: 10.1007/s11914-024-00897-9.
Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers.
Lan H, Wu B, Jin K, Chen Y Front Endocrinol (Lausanne). 2024; 14:1260491.
PMID: 38260135 PMC: 10800370. DOI: 10.3389/fendo.2023.1260491.
Novel insights into voltage-gated ion channels: Translational breakthroughs in medical oncology.
Sakellakis M, Yoon S, Reet J, Chalkias A Channels (Austin). 2023; 18(1):2297605.
PMID: 38154047 PMC: 10761148. DOI: 10.1080/19336950.2023.2297605.
Martiniakova M, Mondockova V, Biro R, Kovacova V, Babikova M, Zemanova N Front Endocrinol (Lausanne). 2023; 14:1113547.
PMID: 36926025 PMC: 10012867. DOI: 10.3389/fendo.2023.1113547.
Skrajnowska D, Jagielska A, Ruszczynska A, Idkowiak J, Bobrowska-Korczak B Nutrients. 2022; 14(6).
PMID: 35334941 PMC: 8951585. DOI: 10.3390/nu14061285.